Basic Info

Common NameO-Desmethylangolensin(F05166)
2D Structure
Description

O-Desmethylangolensin (ODMA) is a metabolite of the soy isoflavone daidzein by intestinal bacteria in approximately 80-90% of persons. Studies suggest beneficial health effects associated with daidzein-metabolizing phenotypes, and there is some small association between ODMA production and some phenotypes. Few dietary factors are associated with daidzein-metabolizing phenotypes. However, it remains unclear why some, but not all, persons harbor ODMA-producing bacteria. ODMA production is inversely associated with age, height, weight, and body mass index. In addition, Asians are less likely than whites to be ODMA producers, and former smokers were more likely than never smokers to be ODMA producers. Investigators have attempted to identify the bacteria involved in ODMA production, and several candidate bacteria were associated, but not definitely identified. ODMA production is correlated with the abundance of methanogens, indicating that the metabolic fate of daidzein may be related to intestinal H(2) metabolism. (A3192, A3193).

FRCD IDF05166
CAS Number21255-69-6
PubChem CID89472
FormulaC15H14O4
IUPAC Name

1-(2,4-dihydroxyphenyl)-2-(4-hydroxyphenyl)propan-1-one

InChI Key

JDJPNKPFDDUBFV-UHFFFAOYSA-N

InChI

InChI=1S/C15H14O4/c1-9(10-2-4-11(16)5-3-10)15(19)13-7-6-12(17)8-14(13)18/h2-9,16-18H,1H3

Canonical SMILES

CC(C1=CC=C(C=C1)O)C(=O)C2=C(C=C(C=C2)O)O

Isomeric SMILES

CC(C1=CC=C(C=C1)O)C(=O)C2=C(C=C(C=C2)O)O

Synonyms
        
            1-Propanone, 1-(2,4-dihydroxyphenyl)-2-(4-hydroxyphenyl)-
        
            O-Desmethylangolensin
        
            o-demethylangolensin
        
            21255-69-6
        
            1-(2,4-dihydroxyphenyl)-2-(4-hydroxyphenyl)propan-1-one
        
            O-Demethylangolesin
        
            AC1L3HY3
        
            AC1Q5ED8
        
            SCHEMBL677731
        
            SCHEMBL12255054
        
Classifies
                

                  
                    Animal Toxin
                  

                
        
Update DateNov 13, 2018 17:07

Chemical Taxonomy

KingdomOrganic compounds
SuperclassPhenylpropanoids and polyketides
ClassAlpha-methyldeoxybenzoin flavonoids
SubclassNot available
Intermediate Tree NodesNot available
Direct ParentAlpha-methyldeoxybenzoin flavonoids
Alternative Parents
Molecular FrameworkAromatic homomonocyclic compounds
SubstituentsAlpha-methyldeoxybenzoin flavonoid - Stilbene - Alkyl-phenylketone - Phenylketone - Phenylpropane - Benzoyl - Aryl alkyl ketone - Aryl ketone - Resorcinol - 1-hydroxy-4-unsubstituted benzenoid - 1-hydroxy-2-unsubstituted benzenoid - Phenol - Monocyclic benzene moiety - Benzenoid - Vinylogous acid - Ketone - Hydrocarbon derivative - Organooxygen compound - Organic oxide - Organic oxygen compound - Aromatic homomonocyclic compound
DescriptionThis compound belongs to the class of organic compounds known as alpha-methyldeoxybenzoin flavonoids. These are flavonoids with a structure based on a 1,2-diphenyl-2-propan-2-one.

Properties

Property NameProperty Value
Molecular Weight258.273
Hydrogen Bond Donor Count3
Hydrogen Bond Acceptor Count4
Rotatable Bond Count3
Complexity309
Monoisotopic Mass258.089
Exact Mass258.089
XLogP3.3
Formal Charge0
Heavy Atom Count19
Defined Atom Stereocenter Count0
Undefined Atom Stereocenter Count1
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Isotope Atom Count0
Covalently-Bonded Unit Count1

ADMET

Model Result Probability
Absorption
Blood-Brain BarrierBBB+0.6150
Human Intestinal AbsorptionHIA+0.9875
Caco-2 PermeabilityCaco2+0.8966
P-glycoprotein SubstrateNon-substrate0.5556
P-glycoprotein InhibitorNon-inhibitor0.9381
Non-inhibitor0.9671
Renal Organic Cation TransporterNon-inhibitor0.8843
Distribution
Subcellular localizationMitochondria0.8873
Metabolism
CYP450 2C9 SubstrateNon-substrate0.6881
CYP450 2D6 SubstrateNon-substrate0.8990
CYP450 3A4 SubstrateNon-substrate0.6575
CYP450 1A2 InhibitorInhibitor0.9266
CYP450 2C9 InhibitorInhibitor0.8820
CYP450 2D6 InhibitorNon-inhibitor0.9047
CYP450 2C19 InhibitorInhibitor0.8215
CYP450 3A4 InhibitorInhibitor0.6496
CYP Inhibitory PromiscuityHigh CYP Inhibitory Promiscuity0.7280
Excretion
Toxicity
Human Ether-a-go-go-Related Gene InhibitionWeak inhibitor0.9460
Non-inhibitor0.9294
AMES ToxicityNon AMES toxic0.9112
CarcinogensNon-carcinogens0.8415
Fish ToxicityHigh FHMT0.9148
Tetrahymena Pyriformis ToxicityHigh TPT0.9913
Honey Bee ToxicityHigh HBT0.6739
BiodegradationNot ready biodegradable0.6818
Acute Oral ToxicityIII0.8425
Carcinogenicity (Three-class)Non-required0.7616

Model Value Unit
Absorption
Aqueous solubility-2.5888LogS
Caco-2 Permeability1.0950LogPapp, cm/s
Distribution
Metabolism
Excretion
Toxicity
Rat Acute Toxicity2.0353LD50, mol/kg
Fish Toxicity0.1726pLC50, mg/L
Tetrahymena Pyriformis Toxicity1.1151pIGC50, ug/L

Targets

General Function:
Zinc ion binding
Specific Function:
Nuclear hormone receptor. Binds estrogens with an affinity similar to that of ESR1, and activates expression of reporter genes containing estrogen response elements (ERE) in an estrogen-dependent manner (PubMed:20074560). Isoform beta-cx lacks ligand binding ability and has no or only very low ere binding activity resulting in the loss of ligand-dependent transactivation ability. DNA-binding by ESR1 and ESR2 is rapidly lost at 37 degrees Celsius in the absence of ligand while in the presence of 17 beta-estradiol and 4-hydroxy-tamoxifen loss in DNA-binding at elevated temperature is more gradual.
Gene Name:
ESR2
Uniprot ID:
Q92731
Molecular Weight:
59215.765 Da
General Function:
Zinc ion binding
Specific Function:
Nuclear hormone receptor. The steroid hormones and their receptors are involved in the regulation of eukaryotic gene expression and affect cellular proliferation and differentiation in target tissues. Ligand-dependent nuclear transactivation involves either direct homodimer binding to a palindromic estrogen response element (ERE) sequence or association with other DNA-binding transcription factors, such as AP-1/c-Jun, c-Fos, ATF-2, Sp1 and Sp3, to mediate ERE-independent signaling. Ligand binding induces a conformational change allowing subsequent or combinatorial association with multiprotein coactivator complexes through LXXLL motifs of their respective components. Mutual transrepression occurs between the estrogen receptor (ER) and NF-kappa-B in a cell-type specific manner. Decreases NF-kappa-B DNA-binding activity and inhibits NF-kappa-B-mediated transcription from the IL6 promoter and displace RELA/p65 and associated coregulators from the promoter. Recruited to the NF-kappa-B response element of the CCL2 and IL8 promoters and can displace CREBBP. Present with NF-kappa-B components RELA/p65 and NFKB1/p50 on ERE sequences. Can also act synergistically with NF-kappa-B to activate transcription involving respective recruitment adjacent response elements; the function involves CREBBP. Can activate the transcriptional activity of TFF1. Also mediates membrane-initiated estrogen signaling involving various kinase cascades. Isoform 3 is involved in activation of NOS3 and endothelial nitric oxide production. Isoforms lacking one or several functional domains are thought to modulate transcriptional activity by competitive ligand or DNA binding and/or heterodimerization with the full length receptor. Essential for MTA1-mediated transcriptional regulation of BRCA1 and BCAS3. Isoform 3 can bind to ERE and inhibit isoform 1.
Gene Name:
ESR1
Uniprot ID:
P03372
Molecular Weight:
66215.45 Da